114
Participants
Start Date
February 1, 2022
Primary Completion Date
June 30, 2023
Study Completion Date
June 30, 2023
Prolgolimab
250 mg Q3W
"State Budgetary Institution of Healthcare of the Arkhangelsk Region Arkhangelsk Regional Clinical Oncology Dispensary (SBHI AR ARCOD)", Arkhangelsk
"State Budgetary Institution of Healthcare Clinical Oncology Dispensary of Chelyabinsk Region (SBIH CODCR)", Chelyabinsk
N.N. Blokhin Russian Cancer Research Center, Moscow
"State Budgetary Healthcare Institution Moscow Clinical Scientific Center funded by Moscow Health Department (SBHI MCSC MHD)", Moscow
"Federal State Budgetary Institution N.N. Petrov Research Institute of Oncology of the Ministry of Healthcare of the Russian Federation, Research Department of the Innovative Methods of Therapeutic Oncology and Rehabilitation", Saint Petersburg
"Federal State Budgetary Institution N.N. Petrov Research Institute of Oncology of the Ministry of Healthcare of the Russian Federation", Saint Petersburg
Lead Sponsor
Biocad
INDUSTRY